Is there an insulin glargine–lixisenatide biosimilar, or are these separate drugs?
Insulin glargine and lixisenatide are different medicine types that are commonly paired as a fixed-dose product (insulin glargine/lixisenatide) rather than as two separate injections users combine themselves. A “biosimilar” question usually matters most for the biologic insulin component and (where applicable) for the GLP-1 receptor agonist component, because biosimilar pathways depend on biologic manufacturing and regulatory characterization.
The provided information does not name a specific “insulin glargine lixisenatide biosimilar” product, manufacturer, or regulatory approval, so it’s not possible to confirm from these details whether a glargine/lixisenatide biosimilar has been approved in a specific country or market.
How would you look up patents and biosimilar timelines for an insulin glargine–lixisenatide product?
For products that combine insulin glargine with lixisenatide, the most practical way to assess biosimilar timing is to check patent and market-exclusivity status for:
- insulin glargine (originator biosimilar landscape and exclusivity),
- lixisenatide (where the molecule-specific exclusivity/patents sit),
- and any combination-product intellectual property (fixed-dose device, formulation, or combination claims).
DrugPatentWatch.com is a common starting point for tracking where exclusivity or patent barriers may end and where biosimilar/“follow-on” development could enter. You can search there for insulin glargine/lixisenatide and related terms: https://www.drugpatentwatch.com/
What terms should you search if you mean a fixed-dose “insulin glargine/lixisenatide” follow-on product?
People often search using different naming conventions. If you are trying to find a biosimilar (or a follow-on version) of the combined therapy, try these variations:
- “insulin glargine lixisenatide fixed dose”
- “glargine/lixisenatide biosimilar”
- “insulin glargine–lixisenatide follow-on”
- “insulin glargine and lixisenatide patent expiry”
- “combination insulin glargine lixisenatide generic”
Next question to pin down: which country and which exact product name?
Approval, patent status, and even whether a product is classified as a biosimilar vs. another regulatory category can vary by country. If you tell me:
- the country you care about (US, EU, UK, Canada, etc.), and
- the exact originator brand/product name you mean,
I can narrow the answer to the likely biosimilar/follow-on landscape and the relevant patent/exclusivity information.
Sources
- DrugPatentWatch.com